藥物交互作用
Apalutamide + Pralsetinib
嚴重程度: 嚴重
Apalutamide and Pralsetinib: major interaction.
最後更新
僅供醫療專業人員參考。本頁為簡要摘要，並非醫療建議，亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。
本頁的臨床內容僅提供英文版。
摘要
Apalutamide is a strong CYP3A4 inducer and can substantially lower pralsetinib exposure. This may lead to reduced antitumor efficacy of pralsetinib.
用白話說明這項交互作用的意義
Apalutamide and Pralsetinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Apalutamide belongs to Endocrine; Pralsetinib belongs to Oncology.
為什麼會發生
Induction of CYP3A4 (and P-gp) by apalutamide increases the metabolic clearance of pralsetinib.
處置方式
Avoid the combination where possible and consider an alternative to apalutamide. If it cannot be avoided, labeling advises doubling the pralsetinib dose from day 7 of the inducer and returning to the original dose after the inducer has been stopped for at least 14 days.
可向藥師詢問的問題
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Apalutamide 的其他交互作用
Pralsetinib 的其他交互作用
常見問題
Can I take Apalutamide with Pralsetinib?
MediHelp rates the interaction as major. Apalutamide and Pralsetinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Apalutamide is a strong CYP3A4 inducer and can substantially lower pralsetinib exposure. This may lead to reduced antitumor efficacy of pralsetinib.
How serious is the interaction between Apalutamide and Pralsetinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination where possible and consider an alternative to apalutamide. If it cannot be avoided, labeling advises doubling the pralsetinib dose from day 7 of the inducer and returning to the original dose after the inducer has been stopped for at least 14 days.
What other medicines interact with Apalutamide?
MediHelp also lists interactions of Apalutamide with, for example, Cabotegravir, Cobicistat, Doravirine. The full list is on the Apalutamide page.
在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查
在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用，並使用劑量工具。
